LAB MANAGEMENT :: ANALYZERS


She notes how the Bio-Rad Laborato- ries BioPlex 2200 System provides clinical labs a testing solution for maximizing efficiency and productivity, streamlin- ing workflows, and minimizing costs. With over 50 multiplex assays available today and more in development, labs


amount of required operator intervention make a big difference. Features such as continuous loading of reagents and con- sumables, automated maintenance and extended onboard stability for quality control and calibration can minimize operator intervention.” The Roche Diagnostics cobas pro inte-


Bio-Rad Laboratories BioPlex 2200 System


can consolidate platforms for autoim- mune, infectious disease, and vitamin D testing on one platform for full automa- tion, trackline connectivity, streamlined workflows, improved turnaround time, and confidence in results. “The BioPlex 2200 System is an easy-


to-use, fully automated, random-access analyzer, utilizing powerful multiplex technology that can produce multiple results simultaneously,” Crisostomo com- mented. “BioPlex 2200 makes managing test panels and complex algorithms as simple as running a single test.”


Reliability and uptime According to Delena Carite, U.S. Group Marketing Manager at Roche Diagnostics, high medical value and positive impacts to patient care are essential factors to take into consideration when choosing an ana- lyzer. She notes how laboratory leaders reported instrument reliability and uptime as most critical for their needs, in addition to an extensive assay menu to complete or expand their offering. “Understanding the performance of an


analyzer in the hands of lab operators, in- cluding the length of time between repair


grated solutions is a scalable and modular solution for mid-to-high volume clinical chemistry and immunochemistry testing needs. Advanced features help labs op- timize workflow, improve productivity, and enhance reliability and turnaround times to support patient care. “Labs can boost efficiency with high- speed analytical units, intelligent sample routing, and industry-leading assay incubation times,” Carite added. “cobas green packs provide more tests/pack and onboard stability of up to six months for chemistry and up to four months for immu- noassays. The solution minimizes operator intervention with continuous loading of reagents and consumables, automated maintenance and automated calibration.”


Operating costs When planning capital budgets for 2022, 68% of lab professionals surveyed said they prioritized technology needed to improve quality/reduce costs.1


Labs op-


erating at lower volumes should evaluate their cost-per-test and turnaround-time, according to Carolina Liquid Chemistries COO Patti Shugart. “For example, small clinical labs


paying more than $5 per Comprehensive Metabolic Profile (CMP) should consider upgrading to a small benchtop chemistry analyzer such as the Medica EasyRA, which offers an extensive menu of urine drug screens and general chemistries with greater ease-of-use, throughput up to 240 tests per hour, and lower cost per test than many other benchtops,” said Shugart. “Labs can quickly outgrow slow, expensive, dry reagent disk-based analyz- ers and should seriously consider upgrad- ing to an analyzer such as the EasyRA.”


Roche Diagnostics cobas pro integrated solutions


visits or down time, is key,” said Carite. “Given the importance of timely turn- around of test results and today’s staffing challenges, speed, predictability, and the


Clinical considerations With regards to analyzer throughput, Richard Noel, Director of North Ameri- can Marketing, LumiraDx, says it really depends on the assay, analyzer, size of lab, and potential clinical impact of the results. “For example, it’s hard to justify running high sensitivity troponin as a batch test once per day if those results are used to de- termine a treatment pathway for a patient in the emergency room (ER),” he said. “It’s interesting that many labs are choosing to bring in next-generation point of care ana-


lyzers that provide lab-comparable results in very short turnaround times. They are usually one test per analyzer but can be loaded and run right when a specimen arrives delivering results in minutes.” To speed up test turnaround time and eliminate “sample transport bottlenecks,” Diebel suggests that some labs could benefit from a decentralized testing model. “This model utilizes compact automated specialty testing analyzers to bring testing closer to the provider for better patient care,” Diebel explains. “These analyzers may be small, but their innovative features and powerful software streamline the opera- tor’s experience. In addition to integrated QC software and LIS connectivity, newer analyzers have managed to eliminate daily maintenance while harmonizing walk-away with up front needs estimations, continu- ous reagent and sample loading, in-process controls, and improved traceability.” The DiaSorin LIAISON XS is a compact


benchtop chemiluminescence immuno- assay analyzer belonging to the scalable DiaSorin LIAISON Analyzer family. This random access, fully automated system enables efficient low to medium volume specialty testing capacity in any labora- tory setting. Its unique menu includes Gastrointestinal testing, QuantiFERON-


DiaSorin LIAISON XS Analyzer


TB Gold Plus and PCT. All tests utilize DiaSorin’s universal reagent Integral format, standardizing operations and results across all LIAISON systems. As Richard Rollins, Sr. Marketing Manager, Nova Biomedical, explains, clinicians treating patients in high acuity areas, such as the intensive care (ICU), need to be able to make very rapid diag- nosis, provide targeted therapy for many complex and rapidly changing diseases, and monitor effectiveness of therapy. “Test menu, turnaround time, and connectivity are the most important considerations when hospitals select instruments for point-of-care testing in ICUs and hospital wards,” said Rollins. “Having an essential profile of stat tests while at the patient bedside is critical for clinicians to manage these high acuity illnesses.”


MLO-ONLINE.COM JUNE 2022 33


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52